Novavax’s 2024-2025 Formula COVID-19 Vaccine Receives Emergency Use Authorization in the US
Shots:
- Novavax’s COVID-19 vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has been approved under the US FDA’s emergency use authorization for individuals (≥12yrs.). The vaccine is also included in the CDC's recommendations issued on Jun 27, 2024
- The EUA was supported by preclinical results depicting the vaccine’s ability of cross-reaction against JN.1 and related viruses (KP.2.3, KP.3, KP.3.1.1 & LB.1.1). The AEs reported in the clinical studies were headache, nausea, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue & malaise
- The vaccine will be available as pre-filled syringes after releasing by the Center for Biologics Evaluation and Research
Ref: Novavax | Image: Novavax
Related News:- Sanofi Partners with Novavax to Co-commercialize COVID-19 Vaccine and Develop Flu-COVID-19 Combination Vaccines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
